Portfolio Companies – Page 3 – BioScience Managers

Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.

13th February 2020/in Armata Pharmaceuticals

Link to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]

ARECOR SIGNS A NEW FEASIBILITY STUDY AGREEMENT WITH TOP FIVE PHARMA COMPANY

13th February 2020/in Arecor

Link to Full Article Pharma partner has an exclusive option to a global, royalty bearing licence Cambridge, UK., 13 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with a top five pharmaceutical company. The pharmaceutical […]

Adherium Raises $5.4 million to Complete Rights Issue and Shortfall Placement

11th February 2020/in Adherium

Link to Full Article 11 February 2020 – Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has successfully reached its target of $5.4 million raised through its Rights Issue by allocating 17,517,309 shares in entitlement subscriptions and 162,206,104 shortfall shares to wholesale and exempt […]

AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update

31st January 2020/in Avita Medical

Link to Full Article U.S. RECELL® System product sales of A$4.66M for fiscal second quarter Valencia, Calif., USA, and Melbourne, Australia, 31 January 2020 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the […]

Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata’s Bacteriophage Development Programs

28th January 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that […]

Saluda Medical Highlights Multiple Presentations Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System at NANS Annual Meeting

24th January 2020/in Saluda Medical

Link to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]

Update on the development of XF drug formulations

20th January 2020/in Destiny Pharma

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on the development of new XF‑platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF‑platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase […]

Congenica launches new application to enable faster analysis of epilepsy and neurodevelopmental disorders

14th January 2020/in Congenica

Link to Full Article Cambridge, United Kingdom – 14th January, 2020 – Congenica, a digital health company enabling rapid analysis of complex genomic data to improve disease characterization and diagnosis, today announced the launch of Congenica Neuro™, a new application on its clinical decision support platform that facilitates faster, more accurate and comprehensive characterization and diagnosis of epilepsy and […]

HIKMA AND ARECOR ANNOUNCE EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALISE READY-TO-USE MEDICINE USING ARESTAT™ TECHNOLOGY

9th January 2020/in Arecor

Link to Full Article Product designed to provide safer, more immediate treatment option for patients London and Cambridge, January 9, 2020 – Hikma Pharmaceuticals PLC (Hikma, Group / LSE: HIK / NASDAQ Dubai: HIK / OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, and Arecor Ltd, the biopharmaceutical company advancing […]

AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo

30th December 2019/in Avita Medical

Link to Full Article Study expected to commence in first half of 2020 Valencia, Calif., USA, and Melbourne, Australia, 30 December 2019 — AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the U.S. Food and […]